



CELLS FOR CELLS

PIONEERING ADVANCED THERAPIES




CELLS FOR CELLS

PIONEERING ADVANCED THERAPIES

Pioneers in advanced therapies

Cells for Cells was born in 2010 with the dream of improving the quality of life of Chilean and global patients, through research, development and commercialization of advanced therapies of international standard, seeking to become the leading exponent in Latam.

Bioinnovation Ecosystem



Cells for Cells: Innovation backed by science



Since 2010, Cells for Cells (C4C) has been promoting regenerative medicine from Chile to the world.

As a spin-off of the Universidad de los Andes, we combine excellence in research with translational development to offer innovative therapies for chronic and degenerative diseases.

Patient

+1000

Patents family

17

Papers

+120

Clinical trials

9



Clínica
Universidad
de los Andes

Value Chain



Research and Development

Research laboratories and facilities for preclinical animal studies



Manufacturing and Scaling


GMP Advanced Therapies Laboratory with ISO9001 certification



Clinical and Market Validation


Affiliation with Clínica Universidad de los Andes

We develop high-impact technologies



Cell Therapy

e.g., MSC therapy for OA



Extracellular Vesicles

*e.g., EV therapy for OA, drug
delivery EV platform*



Bioengineering

*e.g., biomanufacturing
platform for vascular
applications*

Focus areas & next strategic steps



CELL THERAPY



- Development of cryopreserved, ready-to-inject version of **Cellistem®**, conducting phase II trial in OA
- Exploring new MSC application in androgenetic alopecia
- Commercial strategy for the Chilean market

EXTRACELLULAR VESICLES



- Incorporated **EVast Bio** as C4C's first US subsidiary spinoff
- Relocated EV-related IP to the US
- *En route* to engage with FDA in Pre-IND meeting
- Establishing strategic partnership with US CDMO

BIOENGINEERING



- Assessing spinoff feasibility and investor and industry interest for **Avantiss** platform, recently validated in large animals
- Exploring preclinical collaboration with US medtech for **Inkure™ Cartilage** bioink

Our services

GMP Manufacturing as a Service

01. GMP-grade

MSCs 

Available at P5, validated in clinical use,
offered as a fully formulated off-the-
shelf product.

02. CDMO

End-to-end CDMO services
for cell therapies,
extracellular vesicles (EVs),
and other biologics.

03. Analytical & QC

Integrated QC and analytical testing services (ID,
potency, purity, sterility, mycoplasma,
endotoxins) for regulatory-grade release.



CELLS FOR CELLS

PIONEERING ADVANCED THERAPIES

Corporate **Deck**